arrow
S

Shannon R. McCurdy

University of Pennsylvania
H指数:27
被引数:3,201

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pulmonary Alveolar Proteinosis After Allogeneic Stem Cell Transplant in a Patient Undergoing Multiagent Chronic Graft-Versus-Host-Disease Treatment Including Axatilimab

异基因干细胞移植后发生肺泡蛋白沉积症,该患者正接受包括阿萨替利单抗在内的多药慢性移植物抗宿主病治疗

2026-10-050
OAAI
Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age

单倍型与匹配无关供者移植联合移植后环磷酰胺:基于平台的机器学习分析供者年龄

Leukemia
IF13.4
2026-04-150
OAAI
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study

CHARM是老年患者异基因移植后预测老年病发病率和毒性的指标:BMT CTN 1704研究

2025-11-240
OAAI
Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation

移植后环磷酰胺可改善HLA-DPB1错配的无关供者异基因移植的生存率

2025-10-010
PRE
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR

异基因造血细胞供者选择:NMDP/CIBMTR当代指南

2025-07-010
PREAI
Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis

多蛋白、基于血液的生物标志物检测在多发性硬化疾病活动度评估中的实际临床应用价值

2025-04-160
OA
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704

新型复合健康评估风险模型用于老年异基因移植受者:BMT-CTN 1704

2025-03-200
OA
Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation

供者年龄和供者巨细胞病毒血清状态对亲属供者异基因造血干细胞移植后结局的影响

2025-03-120
PRE
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines

美国老年评估实践:针对接受造血细胞移植或嵌合抗原受体T细胞治疗的老年人——移植与细胞治疗学会老年特别兴趣小组与实践指南委员会医师调查

2025-02-010
PRE
Evolving racial/ethnic disparities in AML survival in the novel therapy era

新型疗法时代急性髓系白血病(AML)生存率的种族/族裔差异演变

2025-01-311
PRE
ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies
2024-12-013
PRE
Cytokine-mediated CAR T therapy resistance in AML

细胞因子介导的AML car-t治疗耐药

2024-09-272
PRE
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia
2024-04-181
OAAI
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients
2024-04-015
OAAI